Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, multi-centre, open-label, dose selection study to assess the safety and tolerability of AZD2171 (Recentin) [cediranib] in combination with etoposide and cisplatin (EP) as first line therapy for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.

Trial Profile

A phase I, multi-centre, open-label, dose selection study to assess the safety and tolerability of AZD2171 (Recentin) [cediranib] in combination with etoposide and cisplatin (EP) as first line therapy for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cediranib (Primary) ; Cisplatin; Etoposide
  • Indications Lung cancer; Small cell lung cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Sep 2011 Planned end date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 10 Mar 2011 Planned end date changed from 1 Mar 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 07 Dec 2010 Planned End Date changed from 1 Jan 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top